Phase II Dose-ranging Study of Pyronaridine/Artesunate in Adults Patients With Plasmodium Falciparum Malaria
Status:
Completed
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
The primary trial objective is to determine the clinically effective dose of orally
administered pyronaridine/artesunate (Pyramax®, PA) with a 3:1 ratio to treat adults with
acute, symptomatic, uncomplicated P. falciparum malaria in South East Asia and Africa.
Secondary trial objectives are to determine the safety of once-daily dosing for 3 days of PA
and to explore possible ethnic differences in safety or efficacy.